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1. Introduction 
Pseudoxanthoma elasticum (PXE), also known as Grönblad-Strandberg syndrome, is an 
autosomal recessive disorder mainly affecting skin, eyes and the cardiovascular system due 
to progressive mineralization of elastic fibres (Gheduzzi et al., 2003) in the presence of 
normal levels of calcium and phosphorus in blood and urine.  
 
 
Fig. 1. Dermal biopsy from a patient affected by pseudoxanthoma elasticum (PXE). 
A) Semi-thin section stained with toluidine blue and observed by light microscopy.  
B) Ultrathin section stained with uranyl acetate and lead citrate visualized by transmission 
electron microscopy. Deformed, fragmented and mineralized elastic fibres (E) are clearly 
visible in the reticular dermis of the patient both at low and high magnifications. Collagen 
flowers (arrows) and electron-dense amorphous aggregates (*) can be recognized at the 
ultrastructural level. Bar= 1 µm 
Although the elastic component is dramatically modified in terms of structural 
characteristics and functional properties, many other components of the extracellular matrix, 
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although not calcified, appear altered. Collagen fibrils, for instance, can be laterally fused 
giving rise to collagen flowers, whereas glycoproteins, abnormally secreted within 
connective tissues, are deposited in form of large amorphous aggregates (Gheduzzi et al., 
2003; Pasquali-Ronchetti et al. 1981) (Figure 1). 
The disease is due to mutations in the ABCC6 gene, encoding for a transmembrane protein 
(MRP6) highly expressed in liver, kidney and at a lesser extent in several other tissues, 
although clinically affected. The physiological substrate of MRP6 is still elusive, even though 
functional studies reported that the protein may be involved in the transport of complex 
molecules as glutathione S-conjugate leukotriene C4 and of the synthetic cyclopentapeptide 
BQ123 (an endothelin 1 receptor antagonist) (Belinski et al., 2002; Ilias et al., 2002). Therefore, 
despite the exponentially increased number of studies performed in the last decade, the 
pathogenesis of ectopic calcifications in PXE is a still unresolved puzzle (Uitto et al. 2010).  
PXE is present in all world’s populations, with an estimated prevalence of 1 in 25.000–50.000 
and a 2:1 female to male ratio (Neldner & Struk, 2002). Carriers of only one mutated allele 
do not develop evident clinical manifestations, however they cannot be considered 
completely healthy carriers, since they may be, for instance, at higher risk for cardiovascular 
complications (Vanakker et al., 2008).  
2. Clinical manifestations 
The clinical expression of PXE is heterogeneous, with considerable variation in age of onset, 
progression and severity of the disease, even within the same family and in the presence of 
identical mutations (Gheduzzi et al., 2004; Hu et al., 2003a).  
2.1 Skin 
Patients usually develop skin lesions, mainly at puberty, starting at the posterior side of the 
neck and in flexural areas such as armpits, antecubital and popliteal fossae, which may later 
expand to the inguinal region and the periumbilical area. Alterations are usually in form of 
round yellowish papules, 1–3 mm in diameter, that may coalesce with time into larger 
protruding plaques. In a relevant number of cases, the skin becomes wrinkled and 
redundant hanging in folds (Neldner & Struk, 2002) (Figure 2).  
In the most severely affected patients, lesions on the mucosal membranes, especially on the 
inner side of the lower lip, can be observed. Occasionally, calcium deposits may extrude 
from the skin in advanced state of the disease, a condition described as ‘‘perforating PXE’’ 
(Lund & Gilbert, 1976). Other unusual clinical presentations of PXE include acneiform 
lesions (Heid et al., 1980), chronic granulomatous nodules (Heyl, 1967) and brown macules 
in a reticulate pattern (T.H. Li et al., 1996). 
2.2 Cardiovascular system 
Cardiovascular manifestations, although not frequent, can be observed already before the 
third or fourth decade of life and are mainly related to calcium deposition and degeneration 
of the elastic laminae of medium sized arteries (Mendelsohn et al., 1978). The most common 
cardiovascular complications, in approximately 20-25% of PXE patients, are: diminished or 
absent peripheral vascular pulsations, early onset of reno-vascular hypertension, 
echographic opacities due to calcification of arteries (especially in kidneys, spleen and 
pancreas), arterial hypertension, angina pectoris, intermittent claudication (often regarded 
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as the first sign of accelerated atherosclerosis), gastrointestinal haemorrhages, 
arteriosclerosis and increased risk of myocardial and cerebral infarction (Neldner & Struk, 
2002). Marked calcification of valves and of atrial and ventricular myocardium, as well as 
calcified thrombi, which can result in mitral valve prolapse or stenosis and restrictive 
cardiomyopathy, can be clearly revealed by echocardiography (Rosenzweig et al., 1993). 
 
 
Fig. 2. Typical dermal alterations in PXE. 
Papules (B) as well as wrinkled and redundant skin (A) are classical dermal lesions 
observed in PXE patients 
About 10% of PXE patients experience bleeding complications, especially gastrointestinal 
haemorrhages, due to fragility of calcified submucosal vessels (Golliet-Mercier et al., 2005). 
Bleeding may infrequently affect other organs such as urinary tract, uterus, joints and the 
cerebrovascular system (Bock & Schwegler, 2008; Heaton & Wilson, 1986). 
2.3 Eyes 
PXE is also characterized by severe ocular alterations due to calcification of the Bruch’s 
membrane, that is a thin layer of connective tissue bridging the pigmented retinal 
epithelium to the choriocapillaries and that consists of a network of interwoven elastic and 
collagen fibres (Booij et al., 2010). Eye abnormalities are firstly represented by peau d’orange 
(diffuse mottling of the fundus) that, on an average to 1 to 8 years, precedes angioid streaks 
(greyish irregular lines radiating outward from the optic papilla corresponding to breaks of 
the calcified Bruch’s membrane) (Figure 3). Within 20 years from diagnosis, almost all PXE 
patients develop angioid streaks, that, in the course of the disease, may become pale and 
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give way to a generalized atrophy of the adjacent tissue. In later stages, fibrovascular tissue 
as well as secondary choroidal neovascularization may develop. These new vessels have 
brittle walls, and this may cause recurrent, spontaneous, or trauma-induced retinal 
haemorrhages resulting in disciform scarring of the macula, which is responsible for 
decreased central visual acuity up to legal blindness (Georgalas et al., 2011).  
 
 
Fig. 3. Typical ocular alterations in PXE. 
Elastic fibre mineralization within the Bruch’s membrane, haemorrhage, neovascularization 
and fibrosis (C-D) are the major causes of visual abnormalities. Distortion of the Amsler grid 
(A) is generally the first clinical sign of ocular involvement. Progression of the disease will 
end up with central vision loss (B) up to legal blindness 
2.4 Other organs 
Interestingly, microcalcifications can be detected in several organs, as testis and breast 
(Bercovitch et al. 2003; Vanakker et al., 2006), as well as in liver, kidneys and spleen (59% of 
patients and 23.5% of healthy carriers). On renal and abdominal ultrasonography, for 
instance, a characteristic hyperechogenicity with dotted pattern, possibly reflecting the 
calcified elastic layers of arteries, has been frequently reported (Suarez et al., 1991), as well 
as bilateral nephrocalcinosis (Chraïbi et al., 2007). To be noted, however, that parameters of 
kidney and liver functions are always normal in PXE patients, suggesting that calcification 
does not affect the activity of these organs (Vanakker et al., 2006).  
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During pregnancy, the placenta is abnormal, being hypoplastic and atrophic with focal 
calcifications; moreover, striking anomalies of the elastic lamellae are found in the maternal 
vessels (Gheduzzi et al., 2001). These alterations do not negatively affect pregnancy, 
however early delivery can be recommended if foetus stops growing. 
3. Genetics 
Pseudoxanthoma elasticum is inherited in an autosomal recessive manner. As a general rule, 
each parent of an individual with an autosomal recessive condition carries one copy of the 
mutated gene, without showing or showing very mild signs and symptoms of the disorder. 
In a few cases, however, an affected individual may have one parent without signs and the 
other parent with some sign of the disease. Also these cases have to be considered 
autosomal recessive because the normal-appearing parent, in fact, carries an ABCC6 gene 
mutation, and the affected offspring inherits two altered genes, one from each parent 
(Ringpfeil et al., 2006). This situation is called pseudodominance, because it resembles 
autosomal dominant inheritance, in which one copy of an altered gene is sufficient to cause 
a disorder.  
Because PXE is characterized by calcification of elastic fibres, genes involved in the synthesis 
and assembly of the elastic fibre network were initially considered as primary candidates for 
mutations. These included elastin (ELN) on chromosome 7, elastin-associated microfibrillar 
proteins, such as fibrillin 1 and fibrillin 2 (FBN1 and FBN2) on chromosomes 15 and 5, and 
lysyl oxidase (LOX) also on chromosome 15. However, genetic linkage analyses excluded all 
these chromosomal regions (Christiano et al., 1992; Raybould et al., 1994). Subsequent 
studies, employing positional cloning approaches, provided strong evidence for linkage to 
the short arm of chromosome 16, limiting a region of approximately 500 kb (Le Saux et al., 
1999).  
Examination of the existing genome database revealed that this candidate region contained 
four genes, none of which had actually an obvious connection to elastic fibres or more 
generally to the extracellular matrix, but after a long systematic sequencing approach, it 
appeared that the ABCC6 gene (16p.13.1) is the main site of mutations in PXE (Bergen et al., 
2000; Le Saux et al., 2000; Ringpfeil et al., 2000) (Figure 4).  
This gene, spanning ~73 kb genomic DNA, is composed of 31 exons, belongs to the 
subfamily C of the ABC genes (ATP-binding cassette) and encodes for MRP6 (a 
transmembrane protein of 1503 aminoacids) composed of three hydrophobic membrane 
segments comprising five, six, and six transmembrane spanning domains, respectively, and 
two evolutionary conserved intracellular nucleotide binding folds (NBFs). The NBFs contain 
conserved Walker A and B domains, and a C motif critical for ATP binding and 
transmembrane transporter functions (Chassaing et al., 2005; Hu et al., 2003b) (Figure 5).  
So far, approximately 300 different mutations have been reported in ABCC6 (Costrop et al., 
2010; Gheduzzi et al., 2004; Miksch et al,. 2005; Plomp et al., 2008) and more than 80 have 
been detected in Italian PXE patients. The most frequent sequence changes are missense 
(55%) and nonsense (15%) mutations, as well as small deletions (15%), whereas less frequent 
alterations are represented by splicing errors, large deletions and insertions. Although the 
consequences of splicing mutations have not been investigated, at least 30% of all mutations 
cause a frameshift and the introduction of a stop-codon, which leads to premature chain 
termination. At protein level, the vast majority of mutations involve the cytoplasmatic 
domains and the carboxy-terminal end of MRP6. Mutations especially target the NBF1 and 
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NBF2 domains, and the 8th intracellular loop, consistent with the critical role of NBFs in 
ATP-driven transport. Functional studies have already shown that MRP6 transport is 
abolished by missense mutations located in NBF2 (Ilias et al., 2002).  
 
 
Fig. 4. Localization and structure of the ABCC6 gene on chromosome 16 
Two ABCC6 mutations, R1141X and del (ex23_29), occur very frequently, probably due to 
founder effects and genetic drift. R1141X may produce an instable mRNA which is rapidly 
degraded by nonsense mediated RNA decay (Hu et al., 2003a; Le Saux et al., 2000). The 
frequency of these two recurrent mutations differs according to the population studied: of 
the detected mutations, ex23_29del is observed with a frequency of 28% in USA and 4% in 
Europe, whereas R1141X has a frequency of 4% in USA and 28% in Europe (Le Saux et al., 
2001), with additional differences among European Countries, being 30% in Dutch 
patients (Bergen et al., 2004; Hu et al., 2003b) and about 26% and 13% in Italian and 
French patients, where a common founder effect was identified (Chassaing et al., 2004; 
Gheduzzi et al., 2004). 
By contrast, in Japanese patients, neither R1141X nor ex23_29del mutations were identified, 
whereas mutations 2542delG and Q378X account for 53% and 25%, respectively (Noji et al., 
2004). In South African families of Afrikaaners, mutation R1339C represents more than half 
of the detected mutations, with a common haplotype indicating, also in this case, a founder 
effect (Le Saux et al., 2002).  
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Fig. 5. Schematic drawing showing the typical transmembrane organization of the MRP6 
protein 
The ABCC6 mutation detection rate is around 80-90%, since there are cases in which 
mutations cannot be identified in the coding region on one of the alleles, although the other 
allele harbours a recessive mutation (Chassaing et al., 2004; Gheduzzi et al., 2004); moreover, 
lack of mutation detection in some patients could reflect the occurrence of deletions (for 
example, deletion of exon 15 or deletion of the whole gene). 
To date, no correlations have been established between the clinical phenotype and the 
nature or the position of the mutations (Pfender et al., 2007).  
4. Pathogenesis 
The physiological function and the natural substrate(s) of MRP6 are currently unknown, 
however, because of its homology to MRP1, it has been classified as a multidrug resistance 
associated protein, thus belonging to the large family of membrane proteins that transport 
organic anions and/or other molecules against a concentration gradient at the cost of ATP 
hydrolysis (Borst & Elferink, 2002; Haimeur et al., 2004). The role of MRP6 in drug resistance 
is actually limited to low-level resistance of a small number of chemicals, like etoposide, 
teniposide, doxorubicin and daunorubicin (Belinsky et al., 2002; Kool et al., 1999). 
Consistently with its assumed functional role, MRP6 is highly expressed in liver and 
kidneys being localized to the basolateral side of hepatocytes and of proximal kidney 
tubules, suggesting that it may transport biomolecules from cells into the blood (Bergen et 
al., 2000; Kool et al., 1999; Scheffer et al., 2002).  
However, in spite of the high level of ABCC6 expression, liver and kidney do not suffer from 
mutations in this gene. By contrast, tissues as skin, retina and vessels, which are deeply 
altered in PXE, express very low levels of MRP6 (Bergen et al., 2000; Kool et al., 1999). These 
findings raised a still unsolved dilemma concerning the pathogenesis of PXE: how do 
mutations in a gene expressed primarily in the liver result in the mineralization of 
peripheral connective tissues? 
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To explain the putative mechanisms leading to ectopic calcifications from ABCC6 mutations 
under normal calcium and phosphorus homeostatic conditions, two theories have been 
reported in the literature (Uitto et al., 2010): “the liver metabolic hypothesis” and “the 
peripheral cell hypothesis”. The metabolic hypothesis considers liver dismetabolism the 
only responsible for ectopic calcifications, whereas the peripheral cell hypothesis points to 
the role of mesenchymal cell metabolism on the homeostatic control of connective tissue 
calcifications in PXE.  
The liver metabolic hypothesis postulates that the absence of functional MRP6 activity in 
hepatocytes results in deficiency of circulating factor(s) physiologically required to prevent 
aberrant mineralization (Jiang & Uitto, 2006; Uitto et al., 2010). In support of this hypothesis 
are clinical and experimental observations in PXE patients, as well as in the Abcc6−/− mouse 
(Klement et al., 2005), that serves as a model for human PXE. Firstly, clinical findings in PXE 
patients are rarely present at early childhood and the onset of clinical manifestations as well 
as the slow progression of the disease, due to continued accumulation of minerals in soft 
connective tissues of affected organs, can be regarded as the typical consequence of 
metabolic impairments that worsen with time. Secondly, serum from PXE patients, as well 
as from Abcc6−/− mice, lacks the capacity to prevent calcium/phosphate precipitation in an in 
vitro assay with smooth muscle cell cultures (Jiang et al., 2007). Furthermore, serum from 
PXE patients, when added to the culture medium, has been shown to modify the 
organization of elastic fibres without altering gene expression, thus suggesting the 
involvement of specific circulating factors directly acting on the assembly of elastic fibres 
(Le Saux et al., 2006), even if these changes occur in the absence of any in vitro calcification. 
Finally, recent skin grafting studies in wild-type and Abcc6−/− mice have further focused on 
the importance of circulating factor(s), hypothesizing that the mineralization process can be 
countered or even reversed by modifications of the homeostatic milieu (Jiang et al., 2009). In 
particular, it has been shown that the Abcc6−/− mouse skin graft does not develop 
mineralization, when placed onto the Abcc6+/+ mouse, but calcification occurs in the skin of 
wild-type mouse after grafting onto the Abcc6−/− mouse, indicating that circulating factors in 
the recipient's blood could play a critical role in determining the degree of mineralization, 
irrespective of the graft genotype. However, in these skin graft experiments the possible 
modulation of fibroblast metabolism upon effect of circulating factors cannot be ruled out. 
Actually, several studies have reported alterations in circulating factors in PXE patients, 
such as proteoglycans (Götting et al., 2005; Passi et al., 1996), plasma lipoproteins (Wang et 
al., 2001) and mineralization inhibitors, such as fetuin-A and Matrix Gla Protein (MGP) 
(Hendig et al., 2006, 2008). Moreover, a number of circulating molecules have been shown to 
be modified in the plasma of PXE patients by effect of a systemic altered redox balance 
(Garcia-Fernandez et al., 2008).  
However, a number of questions remain to be elucidated. First of all, in PXE patients, 
despite of the absence and/or of the presence of one or more circulating factor(s), 
mineralization affects only a certain number of elastic fibres and only in peculiar areas of the 
body. Calcification seems, in fact, a rather specific phenomenon, since in PXE patients 
extracellular matrix components other than elastin (i.e. collagens or matrix glycoproteins) 
never undergo mineralization, furthermore, not all elastic fibres are calcified and not all 
areas of affected tissues are clinically involved (Gheduzzi et al.,2003; Pasquali-Ronchetti et 
al., 1981). In addition, the observation that patient’s serum interferes with elastin assembly is 
in agreement with the above mentioned plasma modifications in PXE patients and especially 
with the abnormalities in glycosaminoglycan’s content and species (Maccari et al., 2003, 2008; 
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Passi et al., 1996; Tiozzo Costa et al 1998), since it is well known that these matrix constituents 
are capable to greatly influence tropoelastin assembly (Gheduzzi et al., 2005; Tu & Weiss, 
2008). Finally, if changes in the circulating environment can effectively modify the extent of 
ectopic calcifications, it is not clear why PXE mesenchymal cells, as dermal fibroblasts, 
maintain their abnormal phenotype even when they are cultured in vitro in optimal nutritional 
supplements and conditions far from their original environment (Boraldi et al., 2009). 
Actually, in support to the “peripheral cell hypothesis”, it has been demonstrated that in 
vitro skin fibroblasts isolated from PXE patients exhibit a modified biosynthetic expression 
profile, altered cell-cell and cell-matrix interactions associated with changes in proliferative 
capacity (Boraldi et al., 2009; Quaglino et al., 2000), abnormal synthesis of elastin and of 
glycosaminoglycan/proteoglycan complexes (Passi et al., 1996) and enhanced degradation 
potential due to elevated matrix metalloproteinase-2 activity (Quaglino et al., 2005). 
Consistently, histopathological and ultrastructural observations showed that, in PXE, 
mineralization occurs only on elastic fibres (Gheduzzi et al., 2003; Pasquali-Ronchetti et al., 
1981), suggesting a peculiar composition and/or organization of elastic fibre components 
(Lebwohl et al.,1993; Sakuraoka et al., 1994). By immuno-electron microscopy, it has been 
demonstrated that aberrant matrix proteins known for their high affinity for calcium and 
normally involved in mineralization processes (such as alkaline phosphatase, vitronectin, 
fibronectin, bone sialoprotein, osteonectin and proteoglycans) are accumulated within PXE 
elastic fibres (Contri et al., 1996; Kornet et al., 2004; Passi et al., 1996).  
All these data undoubtedly highlight the importance of mesenchymal cells in the 
pathogenesis of ectopic calcifications, never the less it is still unclear whether these changes 
depend or not upon the expression of the ABCC6 gene in mesenchymal cells (Matsuzaki et 
al., 2005). It has to be noted, in fact, that even normal fibroblasts, possibly due to aberrant 
splicings, do not seem to express the full MRP6 protein (Matsuzaki et al., 2005) and that 
immunologically positive epitopes have been recognized only on membranes of the 
endoplasmic reticulum of isolated dermal fibroblasts (Boraldi et al., 2009). What could be the 
significance and importance of the presence of at least part of MRP6 in the endoplasmic 
reticulum of mesenchymal cells have not been investigated. 
However, in the light of these observations, changes in membrane transport properties 
described in PXE cultured fibroblasts (Boraldi et al., 2003) would seem likely the result of 
the high level of reactive oxygen species (ROS) on the structural organization of cell 
membranes (Boraldi et al., 2009) and consequently on cell permeability. It has been in fact 
demonstrated in vitro (Pasquali-Ronchetti et al., 2006) and in vivo (Garcia-Fernandez et al., 
2008) that PXE is characterized by an altered redox balance. At cellular level, the chronic 
oxidative stress condition is due, at least in part, to the loss of mitochondrial membrane 
potential (ΔΨ (m)) with overproduction of ROS. Consistently, cultured fibroblasts produce 
more malondialdehyde, a product of lipid peroxidation, and accumulate higher amounts of 
carbonylated proteins compared to controls (Boraldi et al., 2009; Pasquali-Ronchetti et al., 
2006). Likewise, in the circulation of patients, the redox unbalance leads to significantly high 
amount of oxidised proteins and lipids, which might have relevant effects  on peripheral 
mesenchymal cells (Garcia-Fenandez et al., 2008). 
Interestingly, among the molecular pathways which are sensitive to the redox potential is 
the vitamin K-cycle that, within connective tissues, is essential for the Ǆ-glutamyl 
carboxylation of MGP (Matrix Gla Protein), a potent inhibitor of calcification in soft 
connective tissues (Schurgers et al., 2008). Consistently, in PXE fibroblasts (Gheduzzi et al., 
2007) and in the Abcc6 -/- mice (Li et al., 2007) there is a reduced carboxylation of MGP.  
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A recent characterization of the PXE fibroblast’s protein profile revealed that numerous 
endoplasmic reticulum-associated proteins are differentially expressed in pathological cells. 
Among these proteins, calumenin and disulfide isomerase are involved in the recycling of 
vitamin K, leaving open the question if insufficient carboxylation of MGP in PXE cells could 




Fig. 6. Drawing illustrating the numerous factors involved in vitamin K cycle. 
Vitamin K represents an important cofactor of protein carboxylation. Within the 
endoplasmic reticulum of mesenchymal cells, MGP (Matrix Gla protein) is activated by 
gamma-carboxylase from the inactive form (Glu-MGP) to the active form (Gla-MGP). 
Protein disulfide isomerase (PDI) and calumenin (CALU) are important modulators of these 
reactions. Warfarin, by inhibiting the action of vitamin K epoxide reductase, reduces the 
efficiency of the carboxylation process and favours the development of vascular 
calcifications. Modified from Wajih (Wajih et al., 2007) 
To further confirm the importance of efficient MGP carboxylation in controlling the 
mineralization process, there are experimental evidences showing that antibodies specific 
for carboxylated (Gla-MGP) and non-carboxylated MGP (Glu-MGP) are differently localized 
within human dermal elastic fibres. In particular, both forms of MGP are rather 
heterogeneously distributed within elastin of control subjects, whereas in PXE patients Glu-
MGP is markedly present in calcified areas and Gla-MGP is exclusively localized at the 
mineralization front (Gheduzzi et al., 2007). Although it has been suggested that MRP6 
could function as a vitamin K transporter from the liver to the periphery, and that, in PXE, 
the mutated protein may prevent connective tissue from an adequate supply of the vitamin 
necessary for efficient carboxylation processes (Borst et al., 2008; Vanakker et al., 2010), in 
vivo and in vitro treatments with different forms of vitamin K do not appear to interfere 
and/or to inhibit the mineralization process (Jiang et al., 2011; Annovi et al., 2011).  
Therefore, it could be suggested that mutated MRP6 in liver and kidney is responsible for 
the altered release in the circulation of factors that modify plasma components, among 
which proteins, lipids and, eventually, other constituents, thus contributing to produce an 
abnormal environment at the periphery, and to influence mesenchymal cell behaviour and 
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metabolism. Among peripheral alterations it would appear that there is an imbalance between 
production and degradation of oxidant species, abnormal protein and glycosaminoglycan 
synthesis, changes in post-translational protein modifications and abnormal DNA-methylation 
(Boraldi et al., 2009). Moreover, the alterations in the in vitro behaviour of PXE fibroblasts may 
suggest that permanent epigenetic changes have occurred, thus causing the inability of these 
cells to produce mature inhibitors and/or modulators of calcification (Figure 7).  
 
 
Fig. 7. Drawing that summarizes the major metabolic abnormalities observed in PXE and the 
relationships between organs and tissues  possibly involved in the pathogenesis of elastic 
fibre calcification. 
Absent or altered expression of the ABCC6 gene in hepatocytes may be responsible for 
abnormal extrusion in the circulation of still unknown factor/s which is/are responsible for 
or contributing to oxidative stress, to ineffective inhibition of ectopic calcification, to 
reduced levels of vitamin K and/or vitamin K derivatives. Therefore, through the 
circulation, abnormal signals could reach mesenchymal cells epigenetically modifying their 
phenotype, i.e. chronic oxidative stress, altered synthesis of tropoelastin,  production of 
glycosaminoglycans (GAGs) or proteoglycans (PGs) with peculiar physical-chemical 
properties, augmented proteolytic potential, lower expression of carboxylated Matrix Gla 
Protein (Gla-MGP), thus causing accumulation of calcium (Ca2+) and phosphate (PO4¯) 
mineral precipitates on elastic fibres. Abnormal products from mesenchymal cells can be 
found in the circulation or in the urine, i.e. parameters of redox balance, desmosines as 
indicators of elastin degradation, heparan sulfate (HS) and chondroitin-sulfate (CS) GAGs 
and inhibitors of calcification as MGP 
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The various levels of mineralization, even within the same tissue, could be explained by the 
heterogeneity of different mesenchymal cell subtypes and their peculiar functional 
imprinting related to structural and functional requirements of organs and tissues (Jelaska et 
al., 1999; Sorrell & Caplan, 2004). 
On the basis of all these considerations, both “the liver metabolic” and “the peripheral cell” 
hypotheses, together, can actually help to understand the pathogenesis of clinical 
manifestations in PXE. On one side, there is the involvement of the liver that, expressing 
MRP6, has an important role in controlling metabolic processes and plasma composition, on 
the other side it cannot be underestimated the crucial role of peripheral mesenchymal cells, 
as fibroblasts, in regulating connective tissue homeostasis.  
5. The role of modifier genes 
Understanding PXE pathogenesis is further complicated by the fact that the age of disease 
onset and the expression of clinical symptoms are highly variable (Gonzales et al., 2009) and 
marked phenotypic variations have been observed in affected siblings bearing the same 
ABCC6 mutation (Gheduzzi et al. 2004). 
Although, there is no evidence for the involvement of other genes in the pathogenesis of 
PXE (Li et al., 2009), however, a number of modifying factors, both genetic and 
environmental, have been suggested to play a role in the phenotypic expression of the 
disease (Hovnanian, 2010).  
One recently identified genetic factor involves polymorphisms in the promoter region of the 
SPP1 gene (secreted phosphoprotein 1, also known as osteopontin) (Hendig et al., 2007). 
Osteopontin is a secreted, highly acidic phosphoprotein that is involved in immune cell 
activation, wound healing, bone morphogenenesis (Denhardt et al., 2001), thus playing a major 
role in regulating the mineralization process in various tissues, including skin and aorta, 
where osteopontin is localized to elastic fibres (Baccarani-Contri et al., 1994). Higher 
expression of this protein has been observed in skin biopsies from PXE patients compared to 
samples from unaffected regions or from healthy individuals (Contri et al., 1996) and also in 
mice suffering from dystrophic cardiac calcification, suggesting that its expression is 
influenced by the Dyscalc1 locus on chromosome 7 (Aherrahrou et al., 2004). Although several 
polymorphisms in the SPP1 gene have been described and associated with various disorders 
such as systemic lupus erythematosus and arteriosclerosis (Giacopelli et al., 2004), the role of 
osteopontin in regulating the calcification process, strongly suggested that sequence variations 
in the SPP1 promoter region might account for the higher expression observed in PXE 
patients, thus affecting the disease outcome. Consistently, mutational screening revealed nine 
different sequence variations, and three SPP1 promoter polymorphisms (c.-1748A>G, c.-
155_156insG and c.244_255insTG), in particular, were significantly associated with PXE. Until 
now, no functional studies have been carried out with the SPP1 promoter polymorphisms c.-
1748>G, whereas the polymorphism variant c.244_245ins TG does not have a major regulatory 
effect. By contrast, the discovery that polymorphism c.155_156insG generates a Runx2-binding 
site opened a new field of investigations, since Runx2-binding sites are in fact very important 
for regulating SSP1 expression in bone tissue (Giacopelli et al., 2004). A constitutive expression 
of Runx2, combined with a glucocorticoids’ supplementation, results in a strong upregulation 
of SPP1 expression and finally in a biological matrix mineralization by primary dermal 
fibroblasts (Phillips et al., 2006). Therefore, polymorphisms in the SPP1 promoter may 
represent a genetic risk factor contributing to PXE susceptibility.  
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Other studies have correlated the incidence of cardiovascular complications in PXE with 
polymorphisms of genes encoding for xylosyltransferase 1 (XT-1) and xylosyltransferase 2 
(XT-2), a set of key enzymes involved in proteoglycan biosynthesis and considered 
biochemical markers of fibrosis (Schön et al., 2006). The altered proteoglycan metabolism, 
already observed in vitro (Passi et al., 1996) and in vivo (Maccari et al., 2003), suggests that 
enzymes from these pathways may function as genetic co-factors in the severity of PXE. 
Furthermore, PXE patients have elevated serum XT-I activity. On the basis of these 
observations Authors suggested a connection between the severity of the disease and 
genetic variations in the XYLT genes (Schön et al., 2006). 
More recent studies have shown that polymorphisms in genes associated with redox balance 
as catalase (CAT), superoxide dismutase 2 (SOD2) and glutathione peroxidase 1 (GPX1) are 
associated with early onset of clinical manifestations (Zarbock et al., 2007), whereas 
polymorphisms of the VEGF gene (vascular endothelial growth factor) are involved in the 
pathogenesis of ocular manifestations (Zarbock et al., 2009). The distribution of 10 single 
nucleotide polymorphisms (SNPs) in the promoter and coding region of the VEGFA gene has 
been evaluated in DNA samples from 163 German patients affected by PXE and in 163 healthy 
subjects. Five SNPs showed significant association with severe retinopathy. The most 
significant association was with polymorphism c.-460C>T. In the light of these results VEGF 
gene polymorphisms might be considered useful prognostic markers for the development of 
PXE-associated retinopathy, thus allowing earlier therapeutic intervention in order to prevent 
loss of central vision, one of the most devastating consequences of PXE (Zarbock et al., 2009). 
By contrast, very few data are available on the role of ABCC6 polymorphisms on the 
occurrence and/or severity of clinical manifestations in PXE patients. The ABCC6 pR1268Q 
polymorphism has been associated with lower plasma triglycerides and higher plasma 
HDL-cholesterol, suggesting that ABCC6 may contribute to modulate plasma lipoproteins 
and possibly cardiovascular complications (Wang et al., 2001). In a larger study conducted 
on a German cohort of PXE patients, in addition to the complete screening of the ABCC6 
gene, the ABCC6 promoter region was also analyzed and the following polymorphisms 
were found: c.-127C>T, c.-132C>T and C.-219A>C. Interestingly, the difference in the c.-
219A>C frequencies between PXE patients and controls was statistically significant and this 
polymorphism appeared located in a transcriptional activator sequence of the ABCC6 
promoter, functioning as a binding site for a transcriptional repressor predominantly found 
in genes involved in lipid metabolism (Schulz et al., 2006), further sustaining a possible 
correlation between ABCC6 and lipid metabolism. 
Surprisingly, the observation that the c.3421C>T loss-of-function mutation on one allele of 
ABCC6 (R1141X) is significantly associated to coronary artery disease (CAD), in the 
apparently normal population (Köblös et al., 2010), was not confirmed in a cohort of Italian 
PXE patients (Quaglino, unpublished data), further sustaining the difficulty to perform a 
genotype-phenotype correlation, although not excluding the possibility that carriers of 
ABCC6 loss-of-function mutations may benefit from cardiovascular prevention programs 
(Vanakker etal., 2008). 
6. Diagnosis and treatments 
In spite of the impressive progress in understanding the genetic/molecular basis of 
inherited diseases, also in PXE, similarly to other genetic disorders, there have been limited 
improvements in terms of treatment and cure. Major advances concern diagnosis, due to 
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ability to recognize a continuously increased number of mutations (mutation detection rate 
varies from 80-90%). Attempts to establish genotype/phenotype correlations have yielded 
little clinically useful information other than the fact that, as PXE patients age, symptoms get 
worse, probably because of progressive accumulation of mineralized elastic fibres, 
associated to other age-related degenerative features (Garcia-Fernandez et al., 2008).  
PXE is an important cause of blindness and of early death from cardiovascular 
manifestations (Neldner, 1988), therefore an early diagnosis is important in order to 
minimise the risk of systemic complications. One of the major problems encountered by 
patients affected by rare diseases, as PXE, is the difficulty to find physicians who are aware 
of the disorder and of the possible related complications. Therefore, strenuous efforts are 
necessary to spread the knowledge on these disorders not only in the scientific community, 
but also among practitioners, who represent the first medical reference point for patients. 
An additional help may derive from the definition of commonly accepted criteria for clinical 
diagnosis, which, in the case of PXE, include the presence of retinal angioid streaks (a 
fluorescein angiogram may be necessary) in combination with characteristic skin lesions 
(calcification of fragmented elastic fibres confirmed by von Kossa stain in a biopsy of lesional 
skin) (Figure 8) with or without a positive family history of PXE (two or more family members 
clinically diagnosed). It is however important to note that mild forms of the disorder can be 
easily overlooked and a negative family history does not exclude the diagnosis. 
 
 
Fig. 8. Demonstration of mineralized elastic fibres is the gold standard diagnostic criteria  
in PXE. 
A) Light microscopy of a dermal biopsy from a PXE patient stained with Von Kossa for the 
visualization of brownish calcified elastin. B-D) Transmission electron microscopy showing 
dramatically deformed and mineralized elastic fibres (arrows) in the dermis of a PXE patient 
(B) and small clinically irrelevant alterations (arrows) in the skin of PXE carriers  
(C), compared to the typical amorphous structure of normal elastic fibres (D). Bars: 1µm 
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Since the discovery of ABCC6 as the PXE associated gene in 2000 (Bergen et al., 2000; Le 
Saux et al., 2000; Ringpfeil et al., 2000), molecular genetic testing have been rapidly 
developed and, although frequently limited to research laboratories or to highly specialized 
centres, they may represent an important diagnostic assessment. The techniques most 
frequently used are sequence analysis and mutation scanning, which are capable to detect 
missense, nonsense and frameshift mutations as well as small deletions and insertions. 
Testing strategies usually involve a first screening of exons in which a large number of 
mutations are located (i.e. exons 24 and 28), and, in case of negative results, the sequencing 
of the other coding regions. Moreover, since a 16.4 kb deletion involving exons 23-29 is 
another recurrent mutation, a specific deletion analysis can be required.  
Analyses performed so far revealed that there is a considerable spectrum of genetic 
mutations (>300), with wide inter- and intra-familial phenotypic variations, and an extreme 
variability in terms of progression of the disease as well as of severity and extent of clinical 
manifestations. It must be reminded that PXE is a systemic disorder and therefore 
management of PXE requires coordinated input from a multidisciplinary team of specialists 
including dermatologist, primary care physician, ophthalmologist, cardiologist, vascular 
surgeon, plastic surgeon, genetics professional, and a nutritionist.  
Moreover, once a diagnosis of PXE has been established, in order to delay and eventually 
manage ocular and cardiovascular complications, patients are encouraged to have 
clinical/instrumental examinations whose frequency may depend on the age of patient, age 
at diagnosis and severity of clinical manifestations. In particular, it is advisable to perform a 
complete dilated eye examination by a retinal specialist, particularly looking for peau 
d'orange and angioid streaks and baseline cardiovascular examination with periodic follow-
up including: echocardiography, cardiac stress testing, and Doppler evaluation of peripheral 
vasculature.  
At present, no specific treatment for PXE exists, in the sense that mineralization of elastic 
fibres cannot be delayed or reverted. Never the less, skin surgery has been successfully 
applied for cosmetic improvement (Ng et al., 1999), as well as peripheral and coronary 
arteries interventions in order to limit vascular complications (Donas et al., 2007; Shepherd 
& Rooke, 2003).  
The only stage of the disease where therapy for ocular complications is possible and 
indicated is whenever a choroidal neovascularization (CNV) has developed (Georgalas et 
al., 2011). Traditional therapeutic options consist of laser photocoagulation (used to halt the 
progression of CNVs, although characterized by high rate of recurrence, visual loss, and 
central scotomas) (Pece et al., 1997) or of photodynamic therapy (PDT) (used to arrest the 
progression of CNVs, even though results appeared less encouraging then expected) 
(Heimann et al., 2005). Experimental surgical procedures, such as macular translocation or 
subfoveal CNV excision (Roth et al., 2005), appeared unsuccessful. More recently, taking 
advantage from the experience on macular degeneration, the intraocular injection of anti-
angiogenic drugs, as avastin and lucentis, actually appeared to be the most effective 
therapeutic options for ocular complications (Verbraak, 2010). 
In the absence of effective treatments specifically targeting pathways leading to ectopic 
calcifications, anectodical reports can be found in the literature concerning the use of drugs 
or of nutritional supplements. For instance, it has been suggested that pentoxifylline and 
cilostazol may ameliorate intermittent claudication (Muir, 2009), however, controlled 
studies of these drugs in PXE patients have not been performed. Interestingly, the ARED 
(Age Related Eye Disease) study suggested that a regimen of antioxidant vitamins could be 
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beneficial in patients with macular degeneration. Given the similarities with PXE (i.e. ocular 
manifestations and altered redox balance) it is possible that the same recommendation can 
be valuable also for PXE (Lecerf & Desmettre, 2010), even though further investigations are 
required to support this hypothesis. By contrast, more promising perspectives, at least in the 
mouse model, seem to be represented by a diet supplemented with an excess of magnesium, 
although the mechanisms of reduced calcifications are still unknown (Gorgels et al., 2010; 
LaRusso et al, 2009) and the effects of long-term treatments with high doses of magnesium 
in humans have not been yet investigated. 
7. PXE-like diseases 
Even though no other phenotypes are known to be associated with mutations in the ABCC6 
gene, PXE-like clinical features, including aberrant mineralization of elastic fibres, have been 
reported in a number of apparently unrelated acquired and genetic clinical conditions 
(Neldner, 1988).  
7.1 Acquired conditions 
Among the acquired conditions, PXE-like cutaneous changes may be associated with 
multiple pregnancy, longstanding end-stage renal disease (Lewis et al., 2006), L-tryptophan 
induced eosinophilia myalgia syndrome (Mainetti et al., 1991), and amyloid elastosis (Sepp 
et al., 1990) as well as after D-penicillamine treatment, cutaneous exposure to calcium salts 
(Neldner & Martinez-Hernandez, 1979), and salpeter (Nielsen et al., 1978). In these cases, 
mineralization of skin may result from metabolic abnormalities affecting calcium and/or 
phosphate homeostasis or from direct deposition of mineral salts on collagen or elastic 
fibres. However, the pathomechanistic details and the role of predisposing genetic factors 
are unknown.  
In papillary dermal elastolysis, white-yellow papules resembling PXE can be observed in 
aged women (60–80 years), although, in contrast to PXE, these lesions are histologically 
characterized by loss of elastin in the papillary dermis (Ohnishi et al., 1998).  
Moreover, elastic fibres similar to those of PXE have been observed in the lesional skin of 
patients with a variety of inflammatory skin diseases in the absence of clinical evidence of 
PXE (Bowen et al., 2007), in calcific elastosis, lipedema, lipodermatosclerosis, granuloma 
annulare, lichen sclerosus, morphea profunda, erythema nodosum, septal panniculitis, basal 
cell carcinoma and fibrosing dermatitis (Bowen et al., 2007; Taylor et al., 2004). 
Even though sporadically, ocular lesions similar to those typical of PXE, have also been 
reported in Paget’s disease, Marfan’s and Ehlers–Danlos syndromes (Gurwood & 
Mastrangelo, 1997) and calcifications of retina, retina vessels and the presence of osseous 
metaplasia have also been noted in patients with renal failure, Coats’ disease, tuberous 
sclerosis and retinocytomas (Miller et al., 2004; Patel et al., 2002). 
Finally it has to be mentioned that ectopic calcifications may occur in the vascular system 
during physiological aging, in atherosclerosis and hypercholesterolemia, hypertension, 
smoking, calcific aortic stenosis, Marfan syndrome, diabetes, renal failure and in smokers 
(Proudfoot & Shanahan, 2001). There are two types of calcifications that occur in arteries: the 
intimal calcification, characteristic of the atherosclerotic plaque and associated with cells and 
collagen, and the medial calcification (also known as Mönckeberg sclerosis) mainly associated 
with elastin. Patients with chronic kidney disease (CKD) frequently display both forms of 
calcification. Another form of vascular calcification also occurs nearly exclusively in CKD 
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patients: calciphylaxis or calcific uremic arteriolopathy. This is a disorder of medial 
calcification of the small arterioles of the skin, resulting in skin necrosis (Moe & Chen, 2003). 
7.2 Genetic conditions 
Unexpectedly, PXE-like cutaneous changes have also been found in approximately 20% of 
patients with beta-thalassemia (beta-thal) and sickle cell anaemia (SCD), that are well 
known severe congenital forms of anemia resulting from the deficient or altered synthesis of 
haemoglobin beta chains (Baccarani-Contri 2001; Fabbri et al., 2009). The first report 
suggesting a link between beta-thal and PXE was based on the observation that angioid 
streaks were actually present in both diseases (Aesopos et al., 1989). Subsequent studies 
confirmed that PXE-like syndrome in beta-thalassemias and SCD, although less severe, is 
histopathologically and clinically identical to inherited PXE consisting of indistinguishable 
cutaneous, ocular and vascular abnormalities due to elastic fibre calcification (Baccarani-
Contri et al., 2001; Bercovitch & Terry, 2004; Hamlin et al., 2003) (Figure 9). In particular, it 
has been observed that beta-thal patients have calcifications of the posterior tibial artery 
(55%), typical skin lesions (20%), angioid streaks (52%) and that one or more of the three 
manifestations are actually present in 85% of the patients (Aessopos et al., 1998). 
Cardiovascular complications have been only sporadically observed, although they include 
intracranial haemorrhages, ischemic strokes, coronary arterial calcification complicated by 
unstable angina, myocardial infarction, mitral valve prolapse, valve calcification and leaflet 
thickening, pericardial thickening, renal artery calcification with arterial hypertension and 
peripheral arterial abnormalities complicated by gastric haemorrhage and intestinal infarcts 
(Aessopos et al., 1997,1998, 2001; Cianciulli et al., 2002; Farmakis et al., 2003). 
 
 
Fig. 9. PXE-like alterations in a patient affected by beta-thalassemia. 
In these patients, papules and skin folds in typical areas of the neck (A) are associated to 
mineralized elastic fibres (E) in the dermis, as visualized by transmission electron 
microscopy (B). Bar: 1 µm 
A genetic link between beta-thalassemia or SCDs and PXE is unlikely. In first instance, no 
mutations in the ABCC6 gene were found in a cohort of beta-thal patients (Hamlin et al., 
2003), moreover, ABCC6 as well as other genes encoding for elastin or elastin associated 
molecules (i.e. fibrillins 1 and 2, elastin-related glycoproteins and lysyl-oxidase) are located 
on chromosomes different from that of the ǃ-globin gene (Ringpfeil et al., 2000) and family 
members who do not have a haemoglobinopathies fail to show any PXE stigmata (Aessopos 
et al., 1994). 
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Never the less, in a study by Martin and coworkers (2006), fifty PXE patients have been 
investigated with the aim to determine the incidence of haemoglobin abnormalities 
typical of thalassemia. No cases of beta thalassemia were diagnosed in this cohort of 
patients, however in 20% of cases a significant but isolated (i.e. without microcytic 
anemia) increase of haemoglobin A2 (HbA2) was observed. The severity of clinical 
manifestations, other than the extent of cutaneous involvement, appeared independent 
from levels of haemoglobin. Therefore, ABCC6 plus beta-globin digenism was ruled out of 
the pathogenesis of PXE, but it could be hypothesized a functional epigenetic reaction 
between ABCC6 and the beta-globin locus, even though reciprocal interactions are clearly 
unequal since the change in ABCC6 transcription occurring during the course of beta 
thalassaemia is responsible for a PXE phenotype, while increased HbA2 during the course of 
PXE has no haematological clinical consequences. 
Interestingly, it has been recently demonstrated that a mouse model of beta-thal (Hbb(th3/+)) 
exhibits a NF-E2-induced transcriptional down-regulation of liver ABCC6 (Martin et al., 
2011), even though there are no evidence for spontaneous calcifications. It has been therefore 
suggested that decreased expression of mrp6 occurring later in life is probably insufficient to 
promote mineralization in the Hbb(th3/+) mouse C57BL/6J genetic background. However, 
these data may indicate that i) other factors, beside ABCC6 expression are involved in the 
pathogenesis of calcifications, ii) responsive fibroblasts or other mesenchymal cells are 
required in order to modify connective tissue homeostasis, and iii) independently from the 
primary gene defect, common pathways may be involved in these disorders. 
Within this context, it has been suggested that the elastic tissue injury in these patients may 
be the result of an oxidative process, induced by the combined and interactive effects of 
different factors (Aessopos et al., 1998; Garcia-Fernandez et al., 2008; Pasquali-Ronchetti et 
al., 2006). Plasma membrane microparticles, derived from the oxidative damage of red cell 
membranes by the effect of denatured hemoglobin products and free iron (Olivieri, 1999), as 
well as unbound fractions of hemoglobin and haem, which exceed the binding capacity of 
haptoglobin and hemopexin in the context of chronic hemolysis, have been considered to 
elicit inflammatory and oxidative reactions (Belcher et al., 2000; Gutteridge & Smith, 
1988). The accumulated and prolonged effects of ROS/free radicals may result in 
disturbance of mesenchymal cell metabolism with structural deterioration of elastic fibres 
(Bunda et al., 2005). Accordingly, oxidative stress constitutes a potential acquired 
mechanism affecting the same molecular pathways, which are implicated in the 
pathogenesis of hereditary PXE.  
The recent observation that a PXE-like phenotype can be observed in patients with 
pronounced deficiency of the vitamin K-dependent clotting factors raises the intriguing and 
exiting possibility that there might an additional pathway, independent of ABCC6, leading 
to the PXE phenotype (Vanakker et al. 2007). 
Congenital deficiency of the vitamin K-dependent factors (VKCFD) is a rare bleeding 
disorder that can be caused either by mutation in the gamma-glutamyl carboxylase gene 
(GGCX) or in the vitamin K epoxide reductase  complex(VKORC) (Oldenburg et al, 2000; 
Pauli et al, 1987). Moreover, acquired forms of the disorder can occur more frequently due 
to intestinal malabsorption of vitamin K (Djuric et al., 2007) or after prolonged treatments 
with vitamin K antagonists as warfarin (Palaniswamy et al., 2011). Vitamin K undergoes 
oxidation-reduction cycling within the endoplasmic reticulum, donating electrons to 
activate specific proteins via enzymatic gamma-carboxylation of glutamate groups before 
being enzymatically re-reduced (Figure 6).  
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Fig. 10. Mineralized elastic fibres in a patient affected by VKFCD. 
A) Light and B) transmission electron microscopy of a skin biopsy. Heavy mineralized 
elastic fibres (arrows) can be seen. Bar: 1µm 
In addition to coagulation factors (II, VII, IX, X, and prothrombin) vitamin K activates 
protein C and protein S, osteocalcin (OC), matrix Gla protein (MGP), periostin, Gas6, and 
other vitamin K-dependent (VKD) proteins that, within bones, support calcium homeostasis 
and the mineralization process, whereas in vessel walls, and possibly in other peripheral 
soft connective tissues, they inhibit calcification, favouring endothelial integrity, cell growth 
and tissue renewal (Kidd, 2010).  
Clinical overlap of PXE and VKCFD was obvious from the skin manifestations of yellowish 
papules or leathery plaques, with dot-like depressions, angioid streaks and/or ocular peau 
d'orange, as well as fragmentation and calcification of elastic fibres in the dermis. Important 
phenotypic differences from PXE included much more severe skin laxity with involvement 
of the trunk and limbs with thick, leathery skin folds rather than confinement to flexural 
areas, and no decrease in visual acuity. By light microscopy, changes in the reticular dermis 
were identical to those typical of PXE, consisting in polymorphous, fragmented, and 
mineralized elastic fibres, as shown by von Kossa stain. At the ultrastructural level, 
however, elastin had a more fragmented and mottled appearance than that typically 
observed in PXE (Vanakker et al., 2007) (Figure 10). In the light of these observations, it has 
been demonstrated in vitro (Gheduzzi et al., 2007) and in vivo (Li et al., 2007) that PXE is 
characterized by low levels of carboxylated-Matrix Gla Protein (Gla-MGP), thus suggesting 
that these changes may play a role in the pathogenesis of PXE, as described in more details 
in paragraph 4.  
8. Conclusions 
Pseudoxanthoma elasticum (PXE) is a rare genetic disorder characterized by mineralization 
of elastic fibres within all connective tissues, although the most important clinical 
manifestations affect skin, eyes and the cardiovascular system. Despite the dramatic 
involvement of the extracellular matrix, the first attempts made by researchers to find out 
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the gene defect among those coding for matrix molecules failed and in 2000 three groups, 
independently, demonstrated that PXE is due to mutations in the ABCC6 gene, that belongs 
to the ABC membrane transporters. To date the physiological substrate of this transporter is 
not known and still elusive are the pathogenetic mechanisms linking a defective cellular 
transporter, mainly expressed in liver and kidney, to ectopic calcification of connective 
tissues. This disease may therefore represent a very interesting example for investigating the 
complexity that regulates molecular pathways and the influence of metabolism on several 
organs/systems. Moreover, there is also evidence that similar endpoints (i.e. clinical and 
histological alterations) can be observed in some patients starting from gene defects 
different from ABCC6 (i.e. beta-thalassemia, vitamin-K dependent coagulation deficiency). 
These data support the importance of using wide-spread technologies as transcriptomic or 
proteomic analyses to have a broader view of the molecular pathways that may be involved 
in the pathogenesis of elastic fibre calcification. Moreover recent findings in the literature 
highlights the role of polymorphisms in other genes that could be responsible for 
phenotypic changes and for a different severity of clinical manifestations in this monogenic 
disorder. 
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